Maija Hollmén

ResearcherID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 10

Top Venues

British journal of cancer

Cancers

Clinical cancer research : an official journal of the American Association for Cancer Research

Molecular cancer therapeutics

University of Turku

University of Turku (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Turku Jan 09 2018

Finland

Principal Investigator :: MediCity

University of Turku Jan 05 2016 - Aug 31 2018

Finland

Junior group leader :: MediCity

University of Turku Sep 01 2014 - Apr 30 2016

Finland

Senior scientist :: Medicity

Institute of Pharmaceutical Sciences/Michael Detmar Jul 01 2011 - Jun 30 2014

Switzerland

Post doctoral fellow :: Pharmacogenomics

Education History

University of Turku Jan 01 2004 - Jun 01 2010

Finland

PHD :: Medical biochemistry and genetics

University of Turku Sep 13 1999 - Jan 01 2004

Finland

MSC :: Health Biosciences/drug development

Publications

Jenna H Rannikko, Maija Hollmén
Clinical landscape of macrophage-reprogramming cancer immunotherapies. British journal of cancer 131 (4) (2024)
Jenna H Rannikko, Maija Hollmén
Clinical landscape of macrophage-reprogramming cancer immunotherapies. British journal of cancer 131 (4) (2024)
Jenna H Rannikko, Maija Hollmén
Clinical landscape of macrophage-reprogramming cancer immunotherapies. British journal of cancer (2024)
Jenna H Rannikko, Maija Hollmén
Clinical landscape of macrophage-reprogramming cancer immunotherapies. British journal of cancer 131 (4) (2024)
Jenna H Rannikko, Petri Bono, Johanna Hynninen, Maija Hollmén
Bexmarilimab activates human tumor-associated macrophages to support adaptive immune responses in interferon-poor immune microenvironments. Cancer immunology research (2023)
Maija Hollmén, Mikael Maksimow, Jenna H Rannikko, Matti K Karvonen, Marita Vainio, Sirpa Jalkanen, Markku Jalkanen, Jami Mandelin
Nonclinical Characterization of Bexmarilimab, a Clever-1-Targeting Antibody for Supporting Immune Defense Against Cancers. Molecular cancer therapeutics 21 (7) (2022)
Catherine Spourquet, Ophélie Delcorte, Pascale Lemoine, Nicolas Dauguet, Axelle Loriot, Younes Achouri, Maija Hollmén, Sirpa Jalkanen, François Huaux, Sophie Lucas, Pierre Van Meerkeeck, Jeffrey A Knauf, James A Fagin, Chantal Dessy, Michel Mourad, Patrick Henriet, Donatienne Tyteca, Etienne Marbaix, Christophe E Pierreux
BRAF V600E Expression in Thyrocytes Causes Recruitment of Immunosuppressive STABILIN-1 Macrophages. Cancers 14 (19) (2022)
Reetta Virtakoivu, Jenna H Rannikko, Miro Viitala, Felix C Vaura, Akira Takeda, Tapio Lönnberg, Jussi Koivunen, Panu M Jaakkola, Annika Pasanen, Shishir Shetty, Maja J A de Jonge, Debbie G J Robbrecht, Yuk Ting Ma, Tanja Skyttä, Anna R Minchom, Sirpa Jalkanen, Matti K Karvonen, Jami Mandelin, Petri Bono, Maija Hollmén
Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (15) (2021)
Stefan Wolf, Jeremy Werner Deuel, Maija Hollmén, Gunther Felmerer, Bong-Sung Kim, Mauro Vasella, Lisanne Grünherz, Pietro Giovanoli, Nicole Lindenblatt, Epameinondas Gousopoulos
A Distinct Cytokine Profile and Stromal Vascular Fraction Metabolic Status without Significant Changes in the Lipid Composition Characterizes Lipedema. International journal of molecular sciences 22 (7) (2021)
Sina Tadayon, Johannes Dunkel, Akira Takeda, Olga Halle, Marika Karikoski, Heidi Gerke, Pia Rantakari, Reetta Virtakoivu, Oliver Pabst, Marko Salmi, Maija Hollmén, Sirpa Jalkanen
Clever-1 contributes to lymphocyte entry into the spleen via the red pulp. Science immunology 4 (33) (2020)

Maija Hollmén.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Maija Hollmén